Aptar nasal system delivers FDA-approved heart rhythm drug CARDAMYST

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/26/2026

1. ORCL
2. SPY
3. FLG
4. META
5. FICO
6. GMAB
7. ACCV
8. LLY
9. TSLA
10. MSFT

Go back to Aptar nasal system delivers FDA-approved heart rhythm drug CARDAMYST

Aptar’s Bidose Nasal System Delivers CARDAMYST™ (etripamil), the First and Only Self-Administered FDA-Approved Nasal Spray for Paroxysmal Supraventricular Tachycardia (PSVT)

December 17, 2025 5:00 PM EST

Novel treatment for PSVT developed with Milestone Pharmaceuticals

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)-- Aptar Group, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that its Bidose (BDS) Liquid Nasal Spray System is the mechanism for delivering the newly approved CARDAMYST (etripamil) Nasal Spray. CARDAMYST received... More